Brokers Issue Forecasts for TRDA Q1 Earnings

Entrada Therapeutics, Inc. (NASDAQ:TRDA - Free Report) - William Blair issued their Q1 2026 earnings per share (EPS) estimates for Entrada Therapeutics in a report released on Thursday, February 27th. William Blair analyst M. Minter forecasts that the company will earn ($0.73) per share for the quarter. The consensus estimate for Entrada Therapeutics' current full-year earnings is $1.12 per share. William Blair also issued estimates for Entrada Therapeutics' Q2 2026 earnings at ($0.76) EPS, Q3 2026 earnings at ($0.81) EPS and Q4 2026 earnings at ($0.86) EPS.

Entrada Therapeutics (NASDAQ:TRDA - Get Free Report) last announced its quarterly earnings data on Thursday, February 27th. The company reported $0.03 EPS for the quarter, topping analysts' consensus estimates of ($0.66) by $0.69. The company had revenue of $12.25 million during the quarter, compared to the consensus estimate of $11.95 million. Entrada Therapeutics had a net margin of 25.53% and a return on equity of 16.11%.

Several other equities analysts have also recently issued reports on TRDA. Oppenheimer increased their target price on Entrada Therapeutics from $25.00 to $28.00 and gave the stock an "outperform" rating in a research note on Wednesday, November 6th. Roth Capital raised Entrada Therapeutics to a "strong-buy" rating in a report on Thursday, December 5th. HC Wainwright reissued a "buy" rating and issued a $20.00 target price on shares of Entrada Therapeutics in a report on Tuesday, February 25th. Finally, Roth Mkm started coverage on shares of Entrada Therapeutics in a research note on Thursday, December 5th. They set a "buy" rating and a $29.00 price target on the stock.

Remove Ads

Entrada Therapeutics Stock Down 0.6 %

NASDAQ TRDA traded down $0.06 during trading hours on Monday, hitting $10.52. 27,921 shares of the stock were exchanged, compared to its average volume of 112,970. The company has a market cap of $393.70 million, a price-to-earnings ratio of 6.62 and a beta of -0.17. Entrada Therapeutics has a 12-month low of $10.19 and a 12-month high of $21.79. The stock has a 50-day moving average of $13.79 and a 200 day moving average of $16.11.

Hedge Funds Weigh In On Entrada Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in TRDA. Mackenzie Financial Corp purchased a new position in shares of Entrada Therapeutics during the 4th quarter worth approximately $251,000. WCG Wealth Advisors LLC grew its holdings in Entrada Therapeutics by 6.2% during the 4th quarter. WCG Wealth Advisors LLC now owns 24,030 shares of the company's stock valued at $415,000 after buying an additional 1,406 shares during the last quarter. Public Employees Retirement System of Ohio increased its position in Entrada Therapeutics by 6.2% during the fourth quarter. Public Employees Retirement System of Ohio now owns 17,259 shares of the company's stock worth $298,000 after buying an additional 1,000 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in shares of Entrada Therapeutics by 152.5% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 35,750 shares of the company's stock worth $618,000 after acquiring an additional 21,594 shares during the last quarter. Finally, State of Wyoming purchased a new stake in shares of Entrada Therapeutics in the fourth quarter valued at $104,000. Institutional investors and hedge funds own 86.39% of the company's stock.

Insider Activity at Entrada Therapeutics

In related news, major shareholder Bioventures 2018 L.P. Mpm sold 22,935 shares of the business's stock in a transaction dated Tuesday, December 10th. The shares were sold at an average price of $20.77, for a total value of $476,359.95. Following the sale, the insider now directly owns 4,402,849 shares in the company, valued at $91,447,173.73. The trade was a 0.52 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 7.59% of the stock is currently owned by company insiders.

Entrada Therapeutics Company Profile

Entrada Therapeutics, Inc, a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1.